Pre-eclampsia
[Pre-eclampsia]
EPTIS Ringversuch Nr. 1144070 | Letze Änderung 2024-05-22 | URL: https://www.eptis.bam.de/pts1144070 https://www.eptis.bam.de/pts1144070
| Name des Anbieters | ||||||||||||||||
| Name des Anbieters | Weqas Weqas | |||||||||||||||
| Ansässig in | United Kingdom | |||||||||||||||
| Sprache(n) | English | |||||||||||||||
| Anmerkungen | The Programme aims to assess the performance of organisations utilising biochemical markers to aid in the diagnosis of pre-eclampsia in pregnancy. The programme aim is to cover the clinically relevant range, i.e. PlGF < 12 pg/ml to ≥100 pg/ml and sFlt-1/PlGF ratio of < 33 to > 110. However, the analytical measuring range will also be assessed where appropriate. The programme is suitable for both Laboratory and POCT applications. Three liquid human samples are distributed monthly, with a minimum of 36 samples distributed over the year covering a wide clinically relevant range. The samples consist of endogenous samples from patients along with a panel of linearly related samples produced from donations from healthy volunteers spiked with PlGF and sFlt-1. They are distributed on a number of occasions over that period which allows for the assessment of the organisation’s and method’s performance, including linearity, bias, within and between batch imprecision. Post – analytical interpretation of pre-eclampsia risk outcome is also assessed. Key Features: - Samples cover analytical and clinical range for sFlt-1 & PIGF. - Post-analytical interpretation of pre-eclampsia risk outcome assessed. - Programme suitable for Lab and POCT applications. - Liquid human samples require no pre-analytical preparation. For more information: https://www.weqas.com/services/eqa/pre-eclampsia/ or contact@weqas.com | |||||||||||||||
| Klassifizierung | ||||||||||||||||
| Produktgruppen |
Health care / medical devices
|
|||||||||||||||
| Prüfgebiete |
Medical analysis
|
|||||||||||||||
| Technische Einzelheiten | ||||||||||||||||
|
||||||||||||||||
| Ringversuchsziele | ||||||||||||||||
| Zielgruppe des Ringversuchs | The programme is suitable for both Laboratory and POCT applications. | |||||||||||||||
| Relevante Rechtsvorschriften oder Normen | ISO/IEC 17043 | |||||||||||||||
| Weitere Ziele | validation of testing methods | |||||||||||||||
| Teilnehmerzahl | ||||||||||||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/IEC 17043 |
|||||||||||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | ||||||||||||||||
| Kosten | ||||||||||||||||
| Teilnahmegebühr | https://www.weqas.com/participantzone/subscription-charges/ | |||||||||||||||
| Regelmässig durchgeführt | Ja (Frequency: Monthly. Samples: 3 x 0.5mL) | |||||||||||||||
| Der Ringversuch wird durchgeführt seit | 2020 | |||||||||||||||
| Kontaktdaten des Anbieters | ||||||||||||||||
| Anbieter | Kontaktperson | |||||||||||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Telefon: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Telefon: 44 (0) 29218 32884 Fax: E-Mail: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
|||||||||||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.